PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Discovery Biology, Discovery Sciences, R&D, AstraZeneca, Cambridge, UK.\', \'Bioscience, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, UK.\', \'Discovery Biology, Discovery Sciences, R&D, AstraZeneca, Cambridge, UK. Julie.douthwaite@astrazeneca.com.\', \'In Vivo Expressed Biologics, Discovery Sciences, R&D, AstraZeneca, Cambridge, UK. Julie.douthwaite@astrazeneca.com.\', \'Charles River Laboratories, Chesterford Research Park, Saffron Walden, CB10 1XL, UK.\', \'Division of Virology, Department of Pathology, Addenbrooke\'s Hospital, Cambridge, UK.\', \'Biologics Engineering, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, UK.\', \'Animal Science and Technologies, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.\', \'Facilities Management, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.\', \'Clinical Operations, Late-Stage Development, Oncology R&D, AstraZeneca, Cambridge, UK.\', \'Department of Medicine, University of Cambridge, Cambridge, UK.\', \'BiologIC Technologies Ltd., Soham, UK.\', \'Oral Product Development, Pharmaceutical Technology and Development, Operations, AstraZeneca, Macclesfield, UK.\', \'Wellcome Sanger Institute, Hinxton, UK.\', \'BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.1038/s41598-022-06888-z
?:doi
?:hasPublicationType
?:journal
  • Scientific reports
is ?:pmid of
?:pmid
?:pmid
  • 35190592
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.533
?:rankingScore_hIndex
  • 122
?:title
  • Heat inactivation of clinical COVID-19 samples on an industrial scale for low risk and efficient high-throughput qRT-PCR diagnostic testing.
?:type
?:year
  • 2022

Metadata

Anon_0  
expand all